Introduction
A variety of stimuli have been shown to induce resting B cells to enter the cell cycle and differentiate into Ig-secreting cells (1) (2) (3) (4) . Recognition of foreign antigens by surface Ig induces B cells to proliferate and differentiate into plasma and memory cells. However, this process requires help from activated T lymphocytes as these cells form conjugates with B lymphocytes, providing signals required for growth and differentiation (5) (6) (7) . The interaction between T and B cells is mediated by several receptor-co-receptor pairs such as CD28-B7, CD40-CD40L, OX40-OX40L and CD5-CD72 (10) (11) (12) (13) (14) . Received 23 October 1997, accepted 30 April 1998 cells (10) (11) (12) (13) (14) (15) . Thus CD40-CD40L and OX40-OX40L appear to be crucial for B cell growth and differentiation, whereas B7-CD28 interaction appears to be more important for T cell activation, which in turn affects the ability of T cells to provide the helper function. The physiological role of the interaction between CD5 and CD72 in the regulation of B cell activation and proliferation remains to be elucidated. CD5 (Ly-1) is a monomeric 67 kDa glycoprotein expressed constitutively on mature T lymphocytes (16, 17) . It is also expressed on a distinct population of B lymphocytes (B-1a), predominant in the peritoneal and pleural cavities (18, 19) . CD5 is a member of the scavenger receptor cysteine-rich family of proteins (20) , and is characterized by the presence of a cysteine-rich extracellular domain-like structure of~100 amino acids (21) (22) (23) ) and a cytoplasmic tail containing the ITAM-like motif YxxP-(x) 8 -YxxL known to be involved in signaling in T and B lymphocytes (23, 24) . Earlier studies with anti-CD5 mAb pointed to a positive role for CD5 in enhancing TCR-mediated signal transduction (25) (26) (27) , whereas recent studies with CD5 knockout animals suggest that CD5 may negatively regulate antigen receptor-mediated signaling in thymocytes and peritoneal B cells (28, 29) .
Very little is known about the possible role of CD5 during cognate interaction of B and T cells. CD5 has been reported to interact with CD72 (Lyb-2), a 45 kDa type II glycoprotein belonging to a family of Ca 2ϩ -dependent C-type lectins, which is expressed as a homodimer at all stages of B cell differentiation, but not on plasma cells. Three different alleles of murine CD72 were shown to bind both murine and human CD5, suggesting that the interaction between CD5 and CD72 is evolutionarily conserved (8, 9) . Antibodies to CD72 induce cell proliferation, increased expression of class II, and mobilization of intracellular calcium in human and mouse B cells; anti-CD72 antibodies have also been shown to prevent the plaque-forming response to the T-dependent antigen, sheep erythrocytes, but not to T-independent antigens (31) (32) (33) . CD5-CD72 interaction has been postulated to have a positive role in contact-mediated, T-dependent B cell activation. We demonstrated that, indeed, CD5 has such a role, using a model system that requires T-B contact for the rescue of a B cell lymphoma from anti-Ig-induced growth inhibition and by showing that anti-CD5 blocked such a rescue (34) . In this system, the growth signals induced by contact-mediated T-B cell interactions required the participation of both T cell CD5 and CD40L. Whereas our data are consistent with a role for CD5 in cognate interactions between T and B cells, using this lymphoma model and several anti-CD72 mAb we found no evidence for the involvement of CD72 in such interactions (34) . To determine if these findings apply to normal B cells, here we investigated the role of CD5 and CD72 in contactdependent, T cell-mediated activation of normal resting B cells. An abstract of this work has been published (35) .
In the present study, using mAb to CD72 and a CD5-Ig fusion protein in proliferation, binding and immunoprecipitation studies, we provide evidence to show that CD5 is an important molecule for contact-mediated, T-dependent B cell activation, and that one ligand for CD5 on B cells is an inducible molecule distinct from CD72.
Methods

Mice
Female DBA/2, BALB/c, C57BL/6 and CBA/N mice, 4-8 weeks old, were obtained from Charles River Laboratories (Wilmington, MA) and housed in a pathogen-free facility at the University of Kentucky. CB17 mice were bred in our animal care facility. Plasmids CD5-Ig, CD7-Ig and CD8-Ig expression vectors were produced at the Bristol-Myers Squibb Pharmaceutical Research Institute (Seattle, WA). These plasmids contain chimeric genes made of the extracellular domain of human CD5 (nucleotides 1-1098) or CD8 (nucleotides 1-611), attached to the Fc portion of human IgG1 (nucleotides 1295-2589). Such fusion molecules often retain the properties of both parent proteins (37) . These plasmid constructs were transiently transfected into COS cells as described previously (38) . Transfected COS cell culture supernatants were collected 10 days posttransfection and the secreted chimeric proteins were purified on a Protein A-Sepharose column (Pharmacia/LKB, Piscataway, NJ). The purified proteins were analyzed by Western blot. They were found to be free of endotoxin by the Limulus amebocyte lysate assay (BioWhittaker, Walkersville, MD).
Cell lines
The isolation and characterization of BKS-2 lymphoma have been described previously (39) . These cells are similar to immature B cells in that they express high levels of IgM but low IgD and are derived from CBA/Ca mice. They are monoclonal and are grown in CBA/N mice as a splenic tumor by serial i.v. injections. The T h 2 clone, F1, isolated from DBA/2 mice and the T h 1 clone, S53, were provided by Drs S. Bryson and A. M. Kaplan respectively (University of Kentucky). The T h 2 clone, D10.G4 was obtained from Dr C. A. Janeway Jr (Yale University). These cells were grown in RPMI supplemented with 20% concanavalin A supernatant and re-stimulated with irradiated (2000 rad) syngeneic spleen cells (clones F1 and S53) or allogeneic C57BL/6 spleen cells (clone D10.G4) once every 15 days. COS cells were obtained from the Bristol-Myers Squibb Pharmaceutical Research Institute and grown in DMEM (Gibco, Grand Island, NY) supplemented with 10% FCS. CD72 a (formerly Lyb 2.1)-transfected L cells were obtained from Dr J. Parnes (Stanford University). The WEHI 231 B cell lymphoma cells were obtained from ATCC (Rockville, MD). The pre-B and mature B cell lines, 70Z and BCL-1, were obtained respectively from Drs J. P. McGillis and E. C. Snow (University of Kentucky). Peripheral blood lymphocytes (PBL) from normal healthy adult volunteers were purified by Ficoll-Hypaque sedimentation. mAb Hybridoma cells producing rat mAb to mouse CD5 (clone 53.7.313, IgG2a) were obtained from ATCC. The anti-class I mAb (H-2K d,b,s,r,q specificity) (clone 34.1.2) was a gift from Dr D. Cohen (University of Kentucky). Hybridoma cells producing anti-CD72 mAb, K10.6, 9.6.1, K24.67 and B9.320 were made available by Drs J. Parnes, N. Tada and S. Kimura, while the 10.1.D2 hybridoma was produced by us (2) . The hybridoma antibodies, 53.7, 10.1.D2 and K10.6, produced as ascites in SCID mice, were purified by ion exchange chromatography on an ABX column (Bakerbond ABX; J. T. Baker Chemical, Phillipsburg, NJ). The purity of mAb was determined by SDS-PAGE. Normal rat-Ig and monoclonal anti-human CD5 mAb were purchased from Sigma (St Louis, MO). The anti-CD3 producing clone, 2C11, was a kind gift of Dr Jeffrey Bluestone (University of Chicago).
Purification of cell populations
T-depleted cells were obtained by treating DBA/2 splenic or peritoneal cells or BKS-2-injected CBA/N spleen cells with a cocktail of anti-CD4 (clone RL-172/4), anti-CD8 (clone 3.155) and anti-Thy-1.2 (clone 13.4) mAb for 30 min on ice followed by addition of rabbit complement (Pel-Freeze, Brown Deer, WI or Lowtox M from Accurate Chemical Scientific, Westbury, NY) for 30 min at 37°C. Adherent peritoneal macrophages were removed by plastic adherence. For proliferation experiments resting B cells were further purified by centrifugation on Percoll density gradients and collecting cells at the 60-70% interface as reported by us previously (31, 32) . Concanavalin A response of T-depleted B cells obtained following this procedure was decreased to 1-3% of the untreated cells, attesting that most of the T cells were removed.
Culture conditions and cell proliferation assays B cells (1.25ϫ10 6 /ml) were cultured in Iscove's/Ham's F12 medium (2,32) (Gibco) supplemented with 5% FCS, in the presence or absence of lipopolysaccharide (LPS; 50 µg/ml), 53.7 (50 µg /ml), K10.6 (50 µg/ml), normal rat Ig (50 µg/ml), 34.1.2 (50 µg/ml), anti-human CD5 (50 µg/ml), CD5-Ig and CD8-Ig at various concentrations. For T-dependent B cell activation, B cells (1.25ϫ10 6 /ml) were cultured with anti-CD3-activated and irradiated (2000 rad) D10, F1 or S53 T cell lines (5ϫ10 3 /ml). Activation of T cells was performed by incubation on anti-CD3 (1.0 µg/ml)-coated plates overnight. These cultures were performed in 96-well flat-bottomed plates (Costar, Cambridge, MA) at 37°C in an atmosphere of 5% CO 2 and 95% air. Cultures were incubated for 48 h and were then pulsed for 4 h with [ 3 H]thymidine (sp. act. 2 Ci/mmol; New England Nuclear, Boston, MA). The cultures were harvested onto glass fiber filters using a Packard automatic cell harvester and thymidine incorporation was determined by a Matrix-96 β-counter (Packard, Downers Grove, IL). For transwell studies, 10 6 B cells were seeded in 24-well dishes (Costar, Cambridge, MA) and 10 5 irradiated anti-CD3-activated T cells were placed in Falcon tissue culture inserts with a permeable membrane of 0.45µm, which were inserted into the same wells. On day 2, the inserts were carefully removed and the remaining B cells were equally distributed into three wells of 96-well plates, pulsed, harvested and counted as described above. B cell blasts were obtained by culturing DBA/2 or CB17 B cells (1.25ϫ10 6 /ml) in IF12 (5% FCS) containing 50 µg/ml of LPS or anti-IgM for 2 days or for the time indicated.
Flow cytometric analyses Lymphocytes (10 6 ) were treated with normal mouse serum (from AKR mice) for 20 min prior to the staining with the respective mAb to minimize non-specific binding. (DuPont NEN, Boston, MA) following the lactoperoxidase method as previously described (40) . Labeled membrane proteins were solubilized with lysis buffer containing 0.5% NP-40, 10 mM Tris-HCl, pH 7.2, 0.15 M NaCl, 0.02% NaN 3 , 10 µg/ml leupeptin, 10 µg/ml aprotinin and 1 mM PSMF for 30 min. The nuclei and macromolecular aggregates were removed by centrifugation at 10,000 g for 20 min, and the resulting lysates were first incubated with Protein A beads (100 µl) (Repligen, Cambridge, MA) overnight at 4°C to remove any Protein A-binding proteins. Then, these lysates (10 8 cells/sample) were incubated with anti-CD72 mAb (50 µg), CD8-Ig (50 µg) or CD5-Ig (50 µg) overnight at 4°C; followed by the addition of Protein A beads (40µl/sample) and incubation for 6 h at 4°C. The precipitates were washed and one half of each precipitate was treated with 2-mercaptoethanol-containing loading buffer and the other half with loading buffer without 2-mercaptoethanol. The remaining lysates were used for sequential immunoprecipitations where samples already precipitated with a given antibody or fusion protein were re-precipitated with the fusion protein or antibody in a fashion identical to that described above. The samples were then electrophoresed on 10% SDS-PAGE gels, which were dried and exposed to X-ray films for 4 days.
Microsequencing of the 77-80 kDa protein CD5-Ig was coupled to activated Affigel-10 beads as prescribed by the manufacturer. CD5-Ig/Affigel-10 beads were incubated with BKS-2 lysates overnight. The beads were then washed and boiled in sample buffer. The supernatant was subjected to SDS-PAGE analysis. The proteins were transferred to PVDF membranes and stained with Coomassie blue. The 77-80 kDa band was excised and provided to the University of Kentucky Protein Sequencing Facility, where this protein was digested at lysine residues and the peptides were separated by HPLC. Four peptides that showed best separation were subsequently selected to be sequenced.
Results
53.7, a monoclonal anti-CD5 antibody, inhibits T cell contactmediated proliferation of B cells
To assess the importance of CD5 in T cell-induced B cell activation, we used anti-CD3-activated, irradiated T h cell clones to induce B cell proliferation. mAb (53.7) against CD5 was added to the cultures of B and T cells as described in Methods. As shown in Since CD5 has been found to bind B cell CD72 (Lyb-2) (8,9), it is possible that antibodies to CD72 also can prevent T cell-induced signaling in this system. Even though anti-CD72 antibodies (both K10.6 and 10.1.D2) are agonistic to B cells, the growth response induced by anti-CD72 was always substantially less (10-25%) than that induced by activated T cells ( Fig. 2A ). So we therefore tested whether occupation of CD72 with antibodies would prevent its presumed interaction with T cell CD5 and thus reduce the B cell response to T cells to the levels observed with anti-CD72 antibodies alone. As shown in Fig. 2(A) , anti-CD72 antibodies (K10.6 and 10.1.D2) did not prevent T cells from efficiently providing growth signals to B cells. Instead, these anti-CD72 antibodies enhanced the T cell-induced B cell growth response. Furthermore, when B cells were cultured with submitogenic concentrations (10 µg/ml) of anti-CD72, there was no direct stimulatory effect nor was there any inhibition of the T cell-induced B cell proliferation (Fig. 2E) . This concentration of anti-CD72 was sufficient to bind all the B cell CD72 molecules as verified by flow cytometry (data not shown). 2 . Anti-CD5 mAb specifically inhibits contact-mediated T h 1 and T h 2 cell-induced B cell proliferation. T-depleted DBA/2 B cells (2.5ϫ10 5 / well) were cultured in IF-12 ϩ 5% FCS medium for 48 h in the presence or absence or various reagents: LPS (50 µg/ml), concanavalin A (2 µg/ml), irradiated T h 1 (S53) and T h 2 (D10) cells (5ϫ10 3 ), and all Ig (50 µg/ml), except in (E) (10 µg/ml). In (A-C) and (E), all reagents were added at the time of initiation of culture. In (D), T or B cells were treated separately with anti-CD5 for 2 h, washed and then added to the culture. A soluble form of CD5 induces proliferation of B cells and this effect can be blocked by an anti-CD5 antibody To further study whether or not CD5 provides a positive costimulatory signal to B cells via its ligand, a chimeric protein made of the extracellular domain of human CD5 attached to the Fc portion of human IgG1 was used as a soluble form of CD5 (see Methods). The human CD5 was utilized since previous studies showed that both murine and human CD5 bound equally well to murine and human forms of CD72 (9) . These studies also demonstrated that murine CD5 bound L cells transfected with mouse or human CD72 gene attesting to a conservation of the CD5-CD72 interaction across species. In this context, the ability of CD5-Ig to substitute for T cells in stimulating resting B cells was examined. As shown in Fig. 3 , CD5-Ig induced DNA synthesis in B cells in a dosedependent manner as indicated by [ 3 H]thymidine incorporation. The signals delivered by CD5-Ig appeared to be specific because they were inhibited by a monoclonal anti-human CD5 antibody. Also, CD8-Ig, a control fusion protein, failed to provide similar stimulation in this system. Furthermore, anti-CD72 antibody in soluble form or bound to Sepharose beads failed to inhibit CD5-Ig-induced B cell proliferation, suggesting that the B cell structures recognized by the two reagents may be distinct ( Table 1) . The proliferation response obtained with soluble anti-CD72 and CD5-Ig was greater than the sum of the response with each of the stimuli. Anti-CD72 beads on their own induced slightly less proliferation than the soluble antibody, and the response with both the beads and CD5-Ig was also more than the sum of Immunofluorescence analyses show that CD5-Ig and anti-CD72 mAb bind different ligands Since we found that an anti-CD5 but not anti-CD72 antibodies inhibited the ability of T cells to induce B cell proliferation, the interaction between CD5 and CD72 was examined using soluble CD5-Ig and flow cytometry. In initial studies, binding of CD5-Ig to resting B cells was found to be minimal. Hence, resting B cells were stimulated for 48 h with LPS, and stained with anti-CD72 mAb and CD5-Ig fusion protein. As illustrated in Fig. 4(A) both an anti-CD72 antibody (10.1.D2) and CD5- a BKS-2 cells were preincubated with medium or anti-CD72 antibodies (5-fold excess over CD5-Ig) for 20 min. Then CD5-Ig was added and the cells were incubated for 30 min. Subsequently the cells were washed and stained with FITC-anti-human IgG. In controls not shown here, it was verified that the anti-human Ig did not react with all the anti-CD72 antibodies used here. MFI: mean fluorescence intensity. Ig (Fig. 4B) but not CD8-Ig (Fig. 4E) bound to the B cell blasts. It appeared that a small number of B cells did not react with CD5-Ig, presumably because the starting B cell population was not synchronized. Competitive binding studies revealed that saturating amounts of anti-CD72 antibody did not inhibit CD5-Ig binding (Fig. 4D versus B) . Similarly CD5-Ig failed to inhibit staining for CD72 (Fig. 4C versus A) . Similar results were obtained using K10.6 antibody as competitor. The lack of competition between CD5-Ig and anti-CD72 was also confirmed with the BKS-2 lymphoma cell line as well as the CD72 transfectants (see below). These findings suggested that CD5 could be binding to a ligand distinct from CD72 on the surface of B cells or that CD5 binds to a site on CD72 not blocked by the 10.1.D2 or K10.6 mAb.
CD5-Ig does not bind to CD72 (Lyb-2.1)-transfected L cells
Since competitive binding studies suggested that CD5-Ig and anti-CD72 antibodies do not compete for the same binding site, the direct binding of CD5 to CD72 was examined by staining CD72-transfected L cells with the soluble CD5- Fig. 5 demonstrated that three different anti-CD72 mAb (10.1.D2, K10.6, and 9.6.1) specifically stained the transfected cells and an excess of CD5-Ig fusion protein failed to prevent the binding of these anti-CD72 antibodies. Moreover, CD5-Ig failed to directly stain these same cells.
Ig. Results in
Anti-CD72 antibodies do not inhibit binding of CD5-Ig to BKS-2 cells
In a reciprocal experiment, we tested the ability of various anti-CD72 antibodies to inhibit the binding of CD5-Ig to BKS-2 cells. The nomenclature of Robinson et al. was employed to describe the CD72 epitopes, CD72.1 and CD72.4, recognized by the anti-CD72 antibodies, 10.1.D2 and K10.6 (41). As summarized in Table 2 , four different anti-CD72 antibodies that are known to bind distinct CD72 epitopes and react with the CD72 on the BKS-2 cells did not compete with CD5-Ig in binding to BKS-2 cells. The small inhibition seen here with K10.6 was not seen in other experiments. Another anti-CD72 antibody B9.320 also failed to significantly inhibit the binding of CD5-Ig to BKS-2 cells though it bound to BKS-2 cells on its own (data not shown). All the four anti-CD72 antibodies were shown to bind to the BKS-2 cells using FITC-anti-mouse IgG2b. These findings further support the hypothesis that CD5 and CD72 have alternate ligands. Hence the molecule(s) identified by CD5-Ig will be called CD5 ligand (CD5L).
CD5 binds to an inducible molecule on activated B cells
Our immunofluorescence data consistently indicated that resting B cells expressed lower densities of CD5L compared with a B lymphoma cell line (BKS-2). Since tumor cells are permanently cycling, we reasoned that activated normal B cells might express higher levels of the CD5L. Moreover, peritoneal B cells expressed CD5L without a need for activation (data not shown) and have also been shown to be undergoing a low level of clonal expansion. Also we wished to determine if a stimulus other than LPS would induce expression of CD5L on B cells. Figure 6 shows that, indeed, anti-IgM activated splenic B cells have an increased surface expression of CD5L. In this system, the maximum level of expression was observed 48 h post-stimulus and then the expression declined slowly. Similar results were obtained with LPS-stimulated B cells (data not shown). On days 1 and 2 there was a slight increase in staining with the control CD8-Ig fusion protein, which was much less than that seen with CD5-Ig and disappeared completely by day 3. The significance of this weak reactivity with CD8-Ig early after B cell activation is unclear at the present time. It could be due to incomplete blocking of the Fc receptor by the normal mouse serum. The staining of B cell blasts (induced with antiIgM or LPS) with CD5-Ig was not inhibited by anti-CD72 antibodies. Also, unlike CD5L which was not detectable on day 0, CD72 was present on B cells from day 0 onwards.
CD5L expression in various lymphoid tissues, resting and activated cells
Having provided evidence for the existence of an alternate ligand for CD5, the CD5-Ig fusion protein was employed to determine the tissue specificity of CD5L expression. As indicated in Table 3 , we found that in mouse, CD5-Ig binds exclusively to B lymphocytes. Expression of CD5L on unstimu- Immunoprecipitations of radiolabeled B cell surface proteins confirm that CD5L is distinct from CD72
In an attempt to define the molecular nature of CD5L, B cells (LPS blasts) and B lymphoma cells (BKS-2) were surface labeled with 125 I. The surface proteins were immunoprecipitated with anti-CD72 antibodies, CD5-Ig or CD8-Ig and separated on SDS-PAGE. Figure 7 compares the apparent mol. wt of the precipitated molecules from labeled LPS blasts and BKS-2 cells. In both LPS blasts (Fig. 7A ) and BKS-2 cells (Fig. 7B ), CD5-Ig precipitated two distinct bands of sizes 77-80 and 38-40 kDa that were not precipitated by either anti-CD72 (K10.6) or by CD8-Ig. Sequential immunoprecipitations confirmed that these bands were specific for CD5, as CD5-Ig precipitated these same two bands from lysates previously precipitated with K10.6 (Fig. 7C, lane 2) . Complete removal of CD72 is shown by the absence of 45 kDa band in anti-CD72 immunoprecipitates of precleared cells (Fig. 7C, lane 3). Also, preclearing with CD5-Ig failed to remove the 45 kDa CD72 molecule as shown in lane 4 of Fig. 7(C) , and the complete removal of CD5L in these lysates is shown by the absence of 77 and 40 kDa bands in CD5-Ig immunoprecipitates in lane 1 of Fig. 7(C) . To determine if the two polypeptide chains of 77-80 and 38-40 kDa were covalently linked with disulfide bonds, SDS-PAGE analysis was performed in the absence of reduction with 2-mercaptoethanol. As shown in Fig. 7D (lane 2) the 38-40 kDa band was still detectable under these conditions, but in repeated experiments the 77-80 kDa band could not be seen in unreduced gels of both 10 and 7.5% (data not shown) composition. Perhaps the 77 kDa chain self-aggregates and does not enter the gel under these conditions. Attesting to the absence of reducing conditions, CD72 migrated as a 90 kDa dimer in the unreduced gels (Fig. 7D, lane 4) . Thus the 38-40 kDa band did not appear to be covalently bound to the 77-80 kDa polypeptide chain.
Microsequencing of the 77-80 kDa protein
The immunoprecipitation data consistently showed that CD5-Ig precipitated higher quantities of the 77-80 kDa band compared to the 38-40 kDa band. In an effort to obtain information about the amino acid sequence of the CD5L, the 77-80 kDa band was solubilized, digested into peptides and separated by reverse-phase chromatography. Four peptides were selected for sequencing which yielded the following amino acid sequences: EITALAPSTMK, QIMFATRNR, SVVT-QTALD and LVVRNTYF. These peptide sequences were screened against the GenBank database (NCBI, Bethesda, MD) and no known protein was found to contain all four peptides. However, the first peptide (EITALAPSTMK) was found to be similar to a sequence present in an actin binding protein (36) . These results suggested the novelty of the CD5L.
Discussion
CD5 has been described as a T cell surface glycoprotein with a role in T cell growth response (25, 42) . Although it has been shown that CD5 can bind to CD72 on B cells, it is unclear if the CD5-CD72 interaction has any role in contactmediated activation of B cells (8, 9) . In this report, using CD5-Ig and anti-CD5 antibody blocking studies, we show that CD5 binds a ligand on activated B cells other than CD72, which we term CD5L. The interaction between CD5 and CD5L plays an important role in contact-mediated, T-dependent B cell activation. 53.7, an anti-mouse CD5, when used in mixed cultures of T and B cells, consistently caused a 60-70% inhibition of T-induced B cell activation (as shown in Figs 1 and 2) . The specificity of this inhibition was confirmed by the fact that pre-incubation of T cells but not B cells with this antibody prevented T cell-induced B cell activation. Anti-CD72 mAb have been shown to be agonistic to B cells (43, 44) ; the results obtained here show that signaling through CD72 synergizes with T h cell-induced B cell activation. This observation is significant because of the reported identity of CD5 ligand as CD72 (8, 9) . This synergistic effect implies that CD72 mAb do not prevent T cells from delivering the co-stimulatory signals. However, anti-CD5 greatly decreases the signal delivery of T cells to B cells. The fact that CD5 but not CD72 is a crucial molecule for the cognate interaction between T and B cells suggests that the CD5-CD72 interaction is not the main mechanism by which T cells deliver their co-stimulatory signals to B cells, raising the possibility of an alternate ligand for CD5 on B cells.
Several other T cell surface molecules have been shown to be involved in the cognate interactions with B cells, like CD40L, CD28 and CTLA-4 (6, 7, (11) (12) (13) 45) . A soluble form of human CD5 was used to study the individual role of CD5 in B cell activation. It is reported here that CD5-Ig is able to induce the proliferation of resting mouse B cells. This proliferation was~5-fold the level of the background growth of B cells. This CD5-Ig effect is specific as CD7-Ig or CD8-Ig molecules do not cause any proliferation and the CD5-Ig effect is inhibited by an anti-human CD5 but not anti-CD72 mAb. These results confirm the importance of CD5 for T cellinduced activation of B cells and the moderate level of proliferation with CD5-Ig alone is consistent with the notion that a single co-stimulatory molecule is not sufficient to induce a full B cell response (3, 6, 7) . This direct stimulatory effect of CD5-Ig fusion protein to mouse B cells is in disagreement with a recent report which showed that purified solublized native human CD5 has no effect on human tonsillar B cells unless they are simultaneously activated with anti-IgM (46) . Unlike in the present studies, the soluble CD5 was thought to act via CD72 since a soluble CD72 fusion protein inhibited the enhancing effect of CD5. The response of B cells to antihuman IgM was enhanced by a maximum of 2-to 3-fold by the soluble CD5 (46) . Presently, the reason for the differing results using these two different approaches is not known but could be due to the difference in species of B cells or the source of B cells (splenic in our study versus tonsillar in the study of Van de Velde and Thielemans). CD5-CD5L or CD5-CD72 interaction may, however, be a redundant mechanism for T-dependent B cell activation since T cells from CD5 knockout mice appear to provide efficient help to B cells to proliferate and differentiate into antibody secreting cells (47) .
In the context of recent observations that CD5 could negatively regulate TCR-or B cell receptor-mediated signaling in thymocytes or B-1 cells, the ability of anti-CD5 to inhibit T cell-induced B cell activation could be due to an inhibition of T h cell activity. However, this is unlikely for three reasons (28, 29) . First, the negative regulatory role of CD5 was shown to be effective in thymocytes but not in peripheral T cells (28) . Second, CD5 inhibited B cell receptor-mediated signaling in B-1 but not splenic B-2 cells that express CD5 upon activation (48) . Third, the direct stimulatory effect of CD5-Ig on B cells suggests that CD5-CD5L interactions have a positive effect on B cell activation. These data further support our previous observation that antibodies to CD5 prevent T helper cell mediated contact-dependent rescue of B lymphoma cells from apoptosis induced by multivalent anti-IgM antibodies (34) and establish a functional role for the ligand pair CD5-CD5L in cognate interactions required for T-dependent B cell activation.
Ligand-counter-receptor relationships between CD5 and CD72 were further investigated in binding studies. These studies revealed that, indeed, CD5 has a ligand on activated B cells, but the interaction between CD5 and this ligand could not be prevented by saturating amounts of blocking anti-CD72 mAb. Also, saturating amounts of CD5-Ig could not prevent the binding of anti-CD72 to their targets on B cells. This finding strongly suggests that CD5 has a ligand other than CD72. Such a possibility is confirmed by the failure of CD5-Ig to stain CD72 transfectants. CD5L is found to be expressed exclusively on B lymphocytes in mouse. It is also found to be expressed in activated human T cells, a result similar to the MHC class II expression pattern in human T lymphocytes (26) . CD5L is not expressed early in B cell development, as it is not detected on bone marrow cells; nor is it expressed at the final stage of B cell development, plasma cells as represented by hybridoma cells, but is expressed on immature B cell lines (BKS-2 and BCL-1) and moderately on mature resting B cells. This ligand is found to be inducible, as activated B cells expressed increasing amounts. The peak of this expression is found to be 48 h for LPS as well as anti-IgM-activated B cells.
Immunoprecipitation of surface iodinated B cell molecules showed that CD5-Ig precipitated two polypeptide chains of 77-80 and 37-40 kDa. These precipitates were shown to be specific by sequential immunoprecipitations, as lysates already precipitated with anti-CD72 mAb (K10.6), when reprecipitated with CD5-Ig, presented the same two molecules. The two molecules immunoprecipitated do not seem to be interacting with one another via disulfide bonding, as they do not dimerize when precipitated under non-reducing conditions. It is still possible that these molecules exist as a heterodimer or oligomer via non-covalent interactions. It is also possible that these molecules are two independent ligands with independent functions, just like the B7-1 and B7-2 molecules, both of which are recognized by CD28 and CTLA-4, but are differentially regulated during B cell activation (13) . Peptide sequences derived from the 77-80 kDa molecule suggest it to be a novel protein. The physiological relevance of the recognition by CD5-Ig of a ligand expressed on B cells was re-enforced by our preliminary studies in which the native CD5 from the T cell line D10 was found to similarly precipitate a 77 kDa polypeptide from BKS-2 cells. Studies are under way to investigate if this molecule is the same as the one precipitated by CD5-Ig.
These results are somewhat surprising in the context of previous reports that showed human and mouse CD5 to bind CD72 in ELISA and immunofluorescence assays (8, 9) but are consistent with another recent report which also failed to observe any binding between CD5 and CD72 (49) . The differing results between this study and those of Van (9) . Although the fusion proteins may not mimic native molecules and thus fail to interact with the true ligand and give negative results, the fact that we as well as Biancone et al. (49) can identify another B cell surface molecule distinct from CD72 as ligand for CD5 suggests that the fusion protein is functional. Also, it is interesting to note that the previous studies on CD5-CD72 interaction never demonstrated the direct interaction by immunochemical means as shown here for the alternate ligand. Our biochemical characterization together with the functional data that anti-CD5 but not anti-CD72 antibody can block T-dependent B cell activation, and that CD5-Ig induces B cell proliferation response and enhances response to anti-CD72 antibody suggests that the CD5L identified here is likely to have a physiological relevance for murine B cell activation. Consistent with this Biancone et al. have shown that the CD5L might have a role in regulating autoantibody production (49) .
This study is in agreement with recently published work by Biancone et al. (49) , showing a human CD5-Ig fusion protein, similar to the one used in our studies, bound to a surface receptor expressed on activated B but not T cells from mice. Also, while both the studies reported here and those of Biancone et al. show that CD5-Ig binds to an inducible molecule expressed on activated B cells that is distinct from CD72, their immunoprecipitation experiments revealed that CD5-Ig was binding to a single polypeptide chain of~40 kDa. Apparently their fusion protein did not precipitate the 77-80 kDa polypeptide that is detected in our immunoprecipitates. These differences could be due to several reasons. (i) We used a monoclonal B cell line, BKS-2 or B cell blasts derived from purified B cells activated with LPS, whereas Biancone et al. used whole spleen cells stimulated with anti-CD3 plus anti-CD28. Their form of B cell activation is T dependent while ours is T independent, which may have slightly different consequences. (ii) We used surface labeling with radioactive iodine whereas Biancone et al. biosynthetically labeled the cells with [ 35 S]methionine. (iii) Even though the CD5-Ig fusion constructs were identical in both the studies, one reason for this difference could be that Biancone et al. produced their fusion protein from electroporated CHO cells, while we produced ours from chloroquine/dextrantransfected COS cells. It is possible that differences in glycosylation of the secreted proteins between the two cell types could result in CD5-Ig from CHO cells binding with slightly different requirements than its homologue from COS cells. Our studies show that the 77-80 kDa species recognized by the COS cell-derived CD5-Ig is also recognized by the naturally occurring T cell-derived CD5 molecule making it physiologically relevant. Nevertheless, the important point of convergence between both sets of studies is that they provide evidence for the existence of a novel cell-surface CD5L that is distinct from CD72.
In summary, we have provided both functional and biochemical evidence for the concept that CD5 has an important role in T cell B cell interactions which is independent of its ability to bind CD72, and that CD5 interacts with CD5L which is biochemically distinct from CD72. 
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